SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. Washington DC: American Psychiatric Association, 2000: 5524
  • 2
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 53744
  • 3
    Laumann EO, Nicolosi A, Glasser DB et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 3957
  • 4
    Simons JS, Carey MP. Prevalence of sexual dysfunctions: results from a decade of research. Arch Sex Behav 2001; 30: 177219
  • 5
    Waldinger MD. Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 2004; 93: 2017
  • 6
    McMahon CG, Abdo C, Incrocci L et al. Disorders of orgasm and ejaculation in men. InLueTF, BassonR, RosenR et al. eds, Sexual Medicine: Sexual Dysfunctions in Men and Women. 2nd International Consultation on Sexual Dysfunctions. Paris: Health Publications, 2004
  • 7
    Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998; 92: 1118
  • 8
    Patrick DL, Althof SE, Pryor JL et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005; 2: 35867
  • 9
    Aschka C, Himmel W, Ittner E, Kochen MM. Sexual problems of male patients in family practice. J Fam Pract 2001; 50: 7738
  • 10
    Rosen R, Porst H, Montorsi F. The premature ejaculation prevalence and attitudes (PEPA) survey: a multinational survey. J Sex Med 2004; 1 (Suppl. 1): 57
  • 11
    Gengo PJ, Giuliano F, McKenna KE et al. Monoaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. J Urol 2005; 173 (Suppl.): 239
  • 12
    Modi N, Dresser M, Desai D. Single- and multiple-dose pharmacokinetics of dapoxetine, a new treatment for premature ejaculation. Submitted to SMSNA meeting, New York, November 2005;in press
  • 13
    Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 (Suppl. 1): 2230
  • 14
    McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159: 19358
  • 15
    McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res 1999; 11: 2416
  • 16
    Pryor JL, Althof SE, Steidle C, Kell S. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. J Urol 2005; 173 (Suppl.): 201
  • 17
    Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med 2005; 2: 12131
  • 18
    Golden RN. Making advances where it matters: improving outcomes in mood and anxiety disorders. CNS Spectr 2004; 9 (Suppl. 4): 1422
  • 19
    Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care 2002; 38: 1116